Prediction of sustained biologic and targeted synthetic DMARD-free remission in rheumatoid arthritis patients.

Burkard, Theresa; Williams, Ross D; Vallejo-Yagüe, Enriqueta; Hügle, Thomas; Finckh, Axel; Kyburz, Diego; Burden, Andrea M

Burkard, Theresa; Williams, Ross D; Vallejo-Yagüe, Enriqueta; Hügle, Thomas; Finckh, Axel; Kyburz, Diego; Burden, Andrea M.

Afiliação

Burkard T; Department of Chemistry and Applied Biosciences, ETH Zurich, Zurich, Switzerland.
Williams RD; Department of Medical Informatics, Erasmus University Medical Centre, Rotterdam, The Netherlands.
Vallejo-Yagüe E; Department of Chemistry and Applied Biosciences, ETH Zurich, Zurich, Switzerland.
Hügle T; Department of Rheumatology, Lausanne University Hospital, University of Lausanne, Lausanne.
Finckh A; Department of Rheumatology, University Hospitals Geneva, Geneva.
Kyburz D; Department of Rheumatology, University Hospital Basel, Basel, Switzerland.
Burden AM; Department of Chemistry and Applied Biosciences, ETH Zurich, Zurich, Switzerland.

Rheumatol Adv Pract ; 5(3): rkab087, 2021.

Article em En | MEDLINE | ID: mdl-34888435

Palavras-chave

Swiss Clinical Quality Management; biologic DMARD; biologics; remission; rheumatoid arthritis; targeted synthetic DMARD; treatment discontinuation

Texto completo

Adicionar na Minha BVS

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Observational_studies / Prognostic_studies / Risk_factors_studies Aspecto: Patient_preference Idioma: En Revista: Rheumatol Adv Pract Ano de publicação: 2021 Tipo de documento: Article País de afiliação: Suíça País de publicação: Reino Unido

Texto completo

Adicionar na Minha BVS

Imprimir

XML

PubMed Links

Buscar no Google